SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Zouater Hichem)
 

Search: WFRF:(Zouater Hichem) > Safety and Effectiv...

  • Backeljauw, Philippe (author)

Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome : Data from the PATRO Children Study

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-07-07
  • S. Karger,2021
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-187366
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-187366URI
  • https://doi.org/10.1159/000515875DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147142268URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Introduction: PATRO Children is an international, observational, postmarketing surveillance study for a biosimilar recombinant human growth hormone (rhGH; somatropin, Omnitrope (R); Sandoz), approved by the European Medicines Agency in 2006. We report safety and effectiveness data for patients with Turner syndrome (TS).Methods: The study population included infants, children, and adolescents with TS who received Omnitrope (R) treatment according to standard clinical practice. Adverse events (AEs) were monitored for safety evaluation, and height velocity (HV), height standard deviation score (HSDS), and HVSDS were calculated to evaluate treatment effectiveness.Results: As of August 2019, 348 TS patients were enrolled from 130 centers. At baseline, 314 patients (90.2%) were prepubertal and 284 patients (81.6%) were rhGH treatment naive. The mean ( range) age at baseline was 9.0 (0.7-18.5) years, and mean (SD) treatment duration in the study was 38.5 (26.8) months. Overall, 170 patients (48.9%) reported AEs, which were considered treatment related in 25 patients (7.2%). One treatment-related serious AE was reported (intracranial hypertension). Mean.HSDS after 3 years of therapy was +1.17 in treatment-naive prepubertal patients and +0.1 in pretreated prepubertal patients. In total, 51 patients (31.1%) reached adult height (AH), 35 of whom were rhGH treatment naive; in these patients, mean (SD) HSDS was -2.97 (1.03) at the start of Omnitrope (R) treatment, and they achieved a mean (SD) AHSDS of -2.02 (0.9).Conclusion: These data suggest that biosimilar rhGH is well tolerated and effective in TS patients managed in reallife clinical practice. Optimization of rhGH dose may contribute to a higher AH. (C) 2021 S. Karger AG, Basel

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Kanumakala, Shankar (author)
  • Loche, Sandro (author)
  • Schwab, Karl Otfried (author)
  • Pfäffle, Roland Werner (author)
  • Höybye, CharlotteKarolinska Institutet (author)
  • Lundberg, Elena,1961-Umeå universitet,Pediatrik(Swepub:umu)ellu0034 (author)
  • Battelino, Tadej (author)
  • Kriström, BeritUmeå universitet,Pediatrik(Swepub:umu)bekr0001 (author)
  • Giemza, Tomasz (author)
  • Zouater, Hichem (author)
  • Karolinska InstitutetPediatrik (creator_code:org_t)

Related titles

  • In:Hormone Research in Paediatrics: S. Karger94:3-4, s. 133-1431663-28181663-2826

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view